Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. TVTX
stocks logo

TVTX

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
99.92M
+84.65%
0.001
-100.19%
100.07M
+59.1%
-0.057
-87.7%
111.33M
+48.86%
0.050
-110.61%
Estimates Revision
The market is revising Upward the revenue expectations for Travere Therapeutics, Inc. (TVTX) for FY2025, with the revenue forecasts being adjusted by 3.04% over the past three months. During the same period, the stock price has changed by 11.66%.
Revenue Estimates for FY2025
Revise Upward
up Image
+3.04%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-48.27%
In Past 3 Month
Stock Price
Go Up
up Image
+11.66%
In Past 3 Month
15 Analyst Rating
up Image0
Wall Street analysts forecast TVTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TVTX is 34.00 USD with a low forecast of 22.00 USD and a high forecast of 47.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Buy
2 Hold
0 Sell
Strong Buy
up Image0
Current: 16.660
sliders
Low
22.00
Averages
34.00
High
47.00
up Image0
Current: 16.660
sliders
Low
22.00
Averages
34.00
High
47.00
Citi
Buy
maintain
$35 -> $32
2025-06-11
Reason
Citi
Price Target
$35 -> $32
2025-06-11
maintain
Buy
Reason
H.C. Wainwright
Buy
initiated
$30
2025-06-11
Reason
H.C. Wainwright
Price Target
$30
2025-06-11
initiated
Buy
Reason
H.C. Wainwright assumed coverage of Travere Therapeutics with a Buy rating and $30 price target. The primary focus is the Filspari commercial launch in the U.S., which is now the only fully approved, non-immunosuppressing, kidney-targeted therapy positioned to potentially replace standard of care, the analyst tells investors in a research note. The firm says Filspari looks to leverage a key opportunity to move into earlier lines of therapy for IgAN.
Citi
Yigal Nochomovitz
Buy
maintain
$35
2025-05-16
Reason
Citi
Yigal Nochomovitz
Price Target
$35
2025-05-16
maintain
Buy
Reason
Cantor Fitzgerald
Prakhar Agrawal
Buy
Reiterates
n/a
2025-04-23
Reason
Cantor Fitzgerald
Prakhar Agrawal
Price Target
n/a
2025-04-23
Reiterates
Buy
Reason
Guggenheim
Vamil Divan
Strong Buy
Reiterates
$47
2025-04-14
Reason
Guggenheim
Vamil Divan
Price Target
$47
2025-04-14
Reiterates
Strong Buy
Reason
Canaccord Genuity
Edward Nash
Strong Buy
Maintains
$45 → $47
2025-04-10
Reason
Canaccord Genuity
Edward Nash
Price Target
$45 → $47
2025-04-10
Maintains
Strong Buy
Reason
Canaccord analyst Edward Nash raised the firm's price target on Travere Therapeutics to $47 from $45 and keeps a Buy rating on the shares. The firm continues to believe Travere's Filspari will be a dominant IgAN therapeutic amongst new approvals and late stage drugs for the treatment of IgAN.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Travere Therapeutics Inc (TVTX.O) is 326.95, compared to its 5-year average forward P/E of -2.41. For a more detailed relative valuation and DCF analysis to assess Travere Therapeutics Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.41
Current PE
326.95
Overvalued PE
48.43
Undervalued PE
-53.26

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
9.88
Current EV/EBITDA
132.73
Overvalued EV/EBITDA
84.79
Undervalued EV/EBITDA
-65.02

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
5.42
Current PS
3.53
Overvalued PS
7.35
Undervalued PS
3.49

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

TVTX News & Events

Events Timeline

(ET)
2025-05-15
16:14:52
Travere Therapeutics announces FDA acceptance of sNDA for Filspari
select
2025-05-01 (ET)
2025-05-01
16:42:10
Travere Therapeutics reports Q1 adjusted EPS (19c), consensus (39c)
select
2025-04-29 (ET)
2025-04-29
07:51:33
Travere, CSL Vifor report EC approval of Filspari for IgA nephropathy
select
Sign Up For More Events
Sign Up For More Events

News

Preview
4.0
07-06Yahoo Finance
Leerink Partners Reiterates a Bullish Stance on Travere Therapeutics (TVTX)

  • Analyst Ratings: Travere Therapeutics, Inc. (NASDAQ: TVTX) has received positive ratings from analysts, including a Buy rating and price targets of $42 and $47 from Leerink Partners and Guggenheim respectively, driven by the full approval of its product Filspari for treating IgA nephropathy.

  • Market Position and Expansion: Despite anticipated competition in the IgAN market, Filspari is expected to maintain a competitive edge due to its complete approval status, while the company also explores expansion into focal segmental glomerulosclerosis with an FDA review underway.

Preview
7.0
07-06Globenewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.  - TVTX

  • Investigation Announcement: Pomerantz LLP is investigating potential securities fraud claims against Travere Therapeutics, Inc. following a significant drop in stock price after the FDA announced an advisory committee meeting regarding the company's drug application.

  • Company Background: Pomerantz LLP, a leading firm in corporate and securities class litigation, has a long history of advocating for victims of securities fraud and has achieved substantial recoveries for class members over its 85-year existence.

Preview
4.0
07-02Benzinga
Demystifying Travere Therapeutics: Insights From 8 Analyst Reviews

  • Analyst Ratings Overview: Recent evaluations of Travere Therapeutics by 8 analysts show a mix of bullish and bearish sentiments, with an average 12-month price target of $33.62, reflecting a slight decline from previous estimates.

  • Financial Performance Insights: Travere Therapeutics exhibits strong revenue growth of 97.54% but faces challenges with a high debt-to-equity ratio and negative return metrics, indicating potential financial risks despite efficient asset management.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Travere Therapeutics Inc (TVTX) stock price today?

The current price of TVTX is 16.66 USD — it has increased 1.71 % in the last trading day.

arrow icon

What is Travere Therapeutics Inc (TVTX)'s business?

Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.

arrow icon

What is the price predicton of TVTX Stock?

Wall Street analysts forecast TVTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TVTX is 34.00 USD with a low forecast of 22.00 USD and a high forecast of 47.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Travere Therapeutics Inc (TVTX)'s revenue for the last quarter?

Travere Therapeutics Inc revenue for the last quarter amounts to 81.73M USD, increased 97.54 % YoY.

arrow icon

What is Travere Therapeutics Inc (TVTX)'s earnings per share (EPS) for the last quarter?

Travere Therapeutics Inc. EPS for the last quarter amounts to -0.47 USD, decreased -73.30 % YoY.

arrow icon

What changes have occurred in the market's expectations for Travere Therapeutics Inc (TVTX)'s fundamentals?

The market is revising Upward the revenue expectations for Travere Therapeutics, Inc. (TVTX) for FY2025, with the revenue forecasts being adjusted by 3.04% over the past three months. During the same period, the stock price has changed by 11.66%.
arrow icon

How many employees does Travere Therapeutics Inc (TVTX). have?

Travere Therapeutics Inc (TVTX) has 385 emplpoyees as of July 17 2025.

arrow icon

What is Travere Therapeutics Inc (TVTX) market cap?

Today TVTX has the market capitalization of 1.48B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free